On September 10, 2026, the Board of Directors appointed Jereme Sylvain as Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. In connection with this promotion, Mr. Sylvain entered into an offer letter providing for an annual base salary of $767,000 and an annual target bonus opportunity equal to 75% of his base salary. He retains eligibility for equity awards under the Company’s Amended and Restated 2015 Equity Incentive Plan and participates in executive benefit plans. Dexcom operates in the medical device industry, specializing in glucose biosensing technology for diabetes management.

On September 10, 2026, DexCom, Inc. announced the appointment of Glenn S. Boehnlein to its Board of Directors, effective immediately. The Board increased its size to thirteen directors and assigned Mr. Boehnlein to the Operations & Innovation Committee and the Audit Committee. Upon appointment, he received an initial equity grant of restricted stock units with a fair value of $500,000, vesting annually over three years. Mr. Boehnlein brings extensive healthcare executive experience, having most recently served as Vice President and Chief Financial Officer at Stryker Corporation from 2016 to 2025. He currently serves on the boards of Inogen, Inc., Agilent Technologies, Inc., and Sutter Health. DexCom operates in the medical technology industry, specializing in glucose biosensing technology for diabetes management.

DexCom, Inc. reported second quarter 2026 financial results on July 30, 2026, announcing revenue of $1.308 billion, a 13% year-over-year increase. GAAP operating income rose to $318.3 million (24.3% margin), while diluted net income per share reached $0.64. The company raised its full-year 2026 revenue guidance midpoint to $5.18–$5.25 billion and increased margins for Non-GAAP Gross Profit, Operating Income, and Adjusted EBITDA. Strategic highlights included positive results from the CONNECT trial for type 2 diabetes patients not using insulin and the launch of a reimagined Stelo app experience. DexCom operates in the medical device industry, specializing in continuous glucose monitoring (CGM) systems and biosensing technology for diabetes management.

Dexcom, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected twelve directors and ratified Deloitte & Touche LLP as the independent auditor. Stockholders also approved the company's executive compensation on a non-binding advisory basis, receiving 277,111,475 votes in favor and 36,664,959 votes against.

Dexcom announced long-range financial targets during its 2026 Investor Day, projecting annual organic revenue growth of at least 10% through 2030 and 2030 non-GAAP margins for gross profit (67-69%), operating profit (29-30%), and adjusted EBITDA (36-37%). Additionally, the company's Board of Directors authorized a new share repurchase program of up to $1.0 billion, which is scheduled to conclude by June 30, 2027.

DexCom, Inc. announced its financial results for the quarter ended March 31, 2026, in a press release issued on April 30, 2026. The filing serves to formally disclose the company's quarterly operational and financial performance.